Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.41 |
| ▸ | CDK1 | P06493 | 7/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 3/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 3/20 | 0.33 |
| ▸ | TDP2 | O95551 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496908 | 0.80 | CA9 (0.37) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL31698083 | 0.80 | CMA1 (0.45) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL10129810 | 0.80 | POLB (0.37) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL29958816 | 0.76 | EPHX2 (0.37) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL24355256 | 0.73 | GSK3B (0.44) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL20106904 | 0.73 | TDP2 (0.42) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL1450511 | 0.72 | GSK3B (0.35) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL17974653 | 0.72 | AHR (0.44) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL496513 | 0.70 | CCNB2 (0.42) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL3726368 | 0.68 | CES1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2021226261-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-1105376-B1 | OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS | SUMITOMO PHARMA (JP) | 2005-02-09 | — | — | EP | disclosed |
| US-6576656-B1 | Such as 1-(2-diethylaminoethyl)-4-trifluoromethyl-6-carbamoyl-3-hydroxy-3-(2 -chlorophenyl)oxindole; growth hormone releaser | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-1105376-A1 | OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000010975-A1 | OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | GSK3B 617/4885CDK5 171/4885CDK5R1 327/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | GSK3B 617/4885CDK5 171/4885CDK5R1 327/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | GSK3B 617/4885CDK5 171/4885CDK5R1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.